Kezar Life Sciences, Inc. KZR, an early-to-mid clinical-stage company, announced initiating a strategic restructuring program to focus on its clinical-stage studies, which is expected to fuel ...
Kezar Life Sciences, Inc. (KZR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors’ and officers’ possible ...
Shares of Kezar Life Sciences (NASDAQ:KZR) fell 11% Thursday after the company said its board of directors had unanimously rejected an unsolicited takeover offer from Concentra Biosciences and adopted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback